World Health Organization : Year 1994 ; World Health Organization, Drug Programme, No. 94.9: Sri Lanka Essential Drugs Project Review and Analysis of the Current Drug Situation Proposal and Plan of Action for 1994- 1998

By George Femando

Book Id: WPLBN0000117828
Format Type: PDF eBook
File Size: 2.2 MB
Reproduction Date: 2005

Title:	World Health Organization : Year 1994 ; World Health Organization, Drug Programme, No. 94.9: Sri Lanka Essential Drugs Project Review and Analysis of the Current Drug Situation Proposal and Plan of Action for 1994- 1998
Author:	George Femando
Volume:
Language:	English
Subject:	Health., Public health, Wellness programs
Collections:	Medical Library Collection, World Health Collection
Historic Publication Date:
Publisher:	World Health Organization


Citation APA MLA Chicago Femando, G. (n.d.). World Health Organization : Year 1994 ; World Health Organization, Drug Programme, No. 94.9. Retrieved from http://gutenberg.us/

Description
Medical Reference Publication

Excerpt
The Mission is impressed by the achievements in the drug field in Sri Lanka since 1985 (refer AM~X4) . Thc Cosmetics, Devices and Drug Act was introduced and regulations have been notified sincc 1985. A National List of Essential Drugs (NLED) has been established at different levels of health care. Procurement, storage and distribution systems have been establishcd. Drug Committees have been formed at public health institutions. Treatment schedules have been developed, and a quality contml laboratory has been functioning. The Sri Lanka Prescriber and the Drug Information Bulletin provide information on some topics to prescribers though not on a regular basis. In spite of these achievements, there is mom for improvement in the implementation of Drug Policy, particularly in thc ficld of monitoring and supervision.

Table of Contents
CONTENTS Page EXECUTIVE SUMMARY AND RECOMMENDATIONS . . . . . . . . . . . . . 1 TERMS OF REFERENCE . . . . . . . . ' . . ; . . . . 1 ..:................ 10 PROGRAMME OF WORK OF THE MISSION . . . . . . . . . . . . . . . . . . . 11 HEALTH POLICY AND HEALTH INFRASTRUCTURE . . . . . . . . . . . . 12 DRUG SITUATION IN SRI LANKA . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Drug policy and management . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Selectionof Esential Dmgs . . . . ;: . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Production . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Pmcurement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Storage and Distribution . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Health Financing . . . . . . . . . . . : . . . . I ....: : . . . . . . . . . . * . . . . . . . . 22 PricingPolicies . . . . . . . . . . . . . . . . . . . . . I . . . . . . . . . . . . . . . . . . . . 23 Quality Assurance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Regulatory Control . . . . . . . . . . . . . . . . . . . . . . . .1 . . . . . . . . . . . . . . . . .2 4 National Drug Quality Assurance Laboratory (NDQAL) . . . . . . . . . . . . . . 27 WHO Certification Scheme . . . . . . . . . . . . . . . . . ; .*................ 28 Good Manufacturing Prilctick (GMP) . . . . . . . . .................. 28 Good Dispensing Practice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 Rational Use of Drugs . . . . . . . . . . . . . . . . . . .: . . . : . . . . . . . . . . . . . . . 30 Prescribing Practices . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 31 Dispensing Practice . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 Drugs Usage by Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33 Drug Information and Adverse Drug 'Reaction Monitoring . . . . . . . . . . . . . 35 Drug Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35 Adverse Drug Reaction Monitoring . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 5 Ethical pro~notiono f drugs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 Hun~anR esource Devcloprnent . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .3 7 Research and Development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38 Technical Cooperation Among Developing Countries (TCDC) . . . . . . . . . . 39 Monitoring and Evaluations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4.0 Drug Supplies and Consumption . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.0 Quality Assurance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 0 Monitoring of Prescribing Practices . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 1